List view / Grid view

Formulation

 

B is for Biosimilars

15 November 2016 | By Niamh Louise Marriott, Digital Content Producer

B is for Biosimilar - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest news and research on the subject of biosimilars.

Life-extending breast cancer drug approved by NICE

3 November 2016 | By Niamh Louise Marriott, Digital Content Producer

NICE has said eribulin, which is also called Halaven and made by Eisai, should be an option for people with locally advanced or metastatic breast cancer...

Issue #5 2016 – Digital edition

20 October 2016 | By European Pharmaceutical Review

In this issue: Biosimilars, Informatics, Ingredients, PAT, HPLC, Microbiology, Product Showcase, Regulation, and much more...

Biosimilars: litigation outlook

20 October 2016 | By

In the Foreword article contributed by Consultant David P. Elder in Issue 3, 2016 of European Pharmaceutical Review, entitled ‘Biosimilars: future prospects’, Dr Elder concluded that it is likely that biosimilars will become increasingly established in both Europe and the United States and that in addition to proteins and peptides,…

Send this to a friend